Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Slides:

Advertisements

Similar presentations

A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.

Advertisements

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Department of Surgical, Oncological and Oral Sciences U.O.C Medical Oncology Director: Prof A. Russo Ovarian cancer Case Report 1 Dr. Lorena Incorvaia,

Clinical and Research Updates in Gynecologic Oncology

Case Discussion: Second Opinion

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Ovarian cancer update Kentucky cancer Registry 9/8/2016

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

SOLO2: Safety, HRQoL With Maintenance Olaparib in Germline BRCA-Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer CCO Independent Conference Highlights*

State of the Art in BRCA-Mutated Ovarian Cancer

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

BRCA, HRR Deficiency, and PARP Inhibitors

The Nurse View.

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

Overall Program Goals. Overall Program Goals Current Approaches.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

PARP Inhibitors and Cancer: What Do You Need to Know?

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Counseling Patients About Germline BRCA Mutations

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Managing gBRCA-Positive Metastatic Breast Cancer

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Treating mRCC After Initial Antiangiogenic Therapy:

Individualizing Care in Ovarian Cancer

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

EHL Technologies in Hemophilia Care

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Advancing Care Across the Spectrum of Pancreatic Cancer

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Maintenance Therapy in Advanced Ovarian Cancer

PARP Inhibitors.

Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian cancer Dr Giorgio Valabrega University of Torino,

Molecular Testing in Ovarian Cancer: Is the Time Now?

Treatment of Locally Advanced Pancreatic Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Changing Field of Melanoma: Ipilimumab.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Oral Prostacyclin Pathway Agents in PAH

Practical Guidance on the Management of Pan-Negative NSCLC

EVOLUTION OF PARP INHIBITORS IN OVARIAN CANCER

Preparing for Checkpoint Inhibitors in Breast Cancer

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Moving Care Forward in Advanced Gastric Cancer

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Clinical Focus.

The Nurse View.

Updates in Best Practices in Non-Small Cell Lung Cancer

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Activity Goals

Epidemiology: Ovarian Cancer

PARP and DNA Repair

BRCA and DNA Repair

Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency

PARP Inhibition in BRCA-like Solid Tumors

Repair Mechanisms and BRCAness

BRCA Testing: When Should it Be Done?

PARP Inhibition: Mechanism of Action

Clinical Outcomes in Patients With BRCA Mutations

PARP Inhibitors in Clinical Trials

Case Study 1

Treatment Options

Anticipated PFS With Standard Treatment

Olaparib as Maintenance Therapy: Study Design

Results of BRCA Testing

Results

ASCO 2014: Cediranib/Olaparib

PFS With Cediranib/Olaparib Superior to Olaparib Alone

PFS Increased With Cediranib/Olaparib Combination

Phase 2: PLD vs Olaparib

Case Study 2

Treatment Approach

Neoadjuvant Chemotherapy (NACT) vs Primary Debulking Surgery (PDS)

Dose-Dense Paclitaxel + Carboplatin vs Conventional Regimen

BRCAness and Response to Chemotherapy

GOG9923

Key Issues for Future Developments of PARP Inhibitors

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)